Journal of veterinary internal medicine · 2026
Evaluation of clinical, ultrasonographic, and clinicopathological findings in dogs with pituitary-dependent hypercortisolism and poor trilostane response.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Golinelli Stefania, Fracassi Federico, Del Baldo Francesca, Leal Rodolfo Oliveira, Pey Pascaline, Feldman Edward C
Аннотация
BACKGROUND: Trilostane is the treatment of choice for pituitary-dependent hypercortisolism (PDH) in dogs, but predictors of a poor response are unclear.
HYPOTHESIS/OBJECTIVES: To identify variables associated with a poor response to trilostane in dogs with PDH.
ANIMALS: Twenty-three dogs with PDH treated with trilostane.
METHODS: Retrospective cohort study. Clinical, clinicopathological, endocrine, ultrasonographic, and treatment data were reviewed. Dogs were classified as good responders (GRs) or nonresponders (NRs) based on clinical outcomes after 4-8 months of trilostane treatment. The primary outcome was treatment response.
RESULTS: Fifteen dogs were GRs and 8 were NRs. At diagnosis, GRs had lower alanine aminotransferase (ALT) (median [IQR] 182 [70-251] vs 330 [224-578] U/L; P = .004), eACTH (14.4 [9.25-29.13] vs 49.2 [34.35-62.35] pg/mL; P = .007), and pre-ACTH cortisol (4.28 [3.07-6.52] vs 9.0 [6.57-19.40] μg/dL; P = .019) than NRs. Bilateral adrenomegaly was more frequent in NRs (8/8) than in GRs (9/15; P = .007). At T1, NRs required more rechecks (median [IQR] 7 [6-7] vs 3 [3-5]; P < .001) and higher trilostane doses (3.25 [3-5.75] vs 1.22 [0.66-1.60] mg/kg q12h; P < .001). After false discovery rate adjustment, ALT, eACTH, alopecia, and bilateral adrenomegaly remained significant (q = 0.047 for each). All GRs achieved complete clinical resolution within 4 months of treatment initiation.
CONCLUSIONS AND CLINICAL IMPORTANCE: Higher baseline ALT, eACTH, and pre-ACTH cortisol, as well as bilateral adrenomegaly, were associated with a poor response to trilostane. A lack of improvement by 4-8 months and the need for higher doses or more rechecks supports early therapeutic reassessment.
HYPOTHESIS/OBJECTIVES: To identify variables associated with a poor response to trilostane in dogs with PDH.
ANIMALS: Twenty-three dogs with PDH treated with trilostane.
METHODS: Retrospective cohort study. Clinical, clinicopathological, endocrine, ultrasonographic, and treatment data were reviewed. Dogs were classified as good responders (GRs) or nonresponders (NRs) based on clinical outcomes after 4-8 months of trilostane treatment. The primary outcome was treatment response.
RESULTS: Fifteen dogs were GRs and 8 were NRs. At diagnosis, GRs had lower alanine aminotransferase (ALT) (median [IQR] 182 [70-251] vs 330 [224-578] U/L; P = .004), eACTH (14.4 [9.25-29.13] vs 49.2 [34.35-62.35] pg/mL; P = .007), and pre-ACTH cortisol (4.28 [3.07-6.52] vs 9.0 [6.57-19.40] μg/dL; P = .019) than NRs. Bilateral adrenomegaly was more frequent in NRs (8/8) than in GRs (9/15; P = .007). At T1, NRs required more rechecks (median [IQR] 7 [6-7] vs 3 [3-5]; P < .001) and higher trilostane doses (3.25 [3-5.75] vs 1.22 [0.66-1.60] mg/kg q12h; P < .001). After false discovery rate adjustment, ALT, eACTH, alopecia, and bilateral adrenomegaly remained significant (q = 0.047 for each). All GRs achieved complete clinical resolution within 4 months of treatment initiation.
CONCLUSIONS AND CLINICAL IMPORTANCE: Higher baseline ALT, eACTH, and pre-ACTH cortisol, as well as bilateral adrenomegaly, were associated with a poor response to trilostane. A lack of improvement by 4-8 months and the need for higher doses or more rechecks supports early therapeutic reassessment.